6 Incredible Reasons to Invest in Eli Lilly
Sold under the brand names Mounjaro and Zepbound, tirzepatide has been an incredible growth driver for Eli Lilly. In 2022 -- the year it was first approved in the U.S. -- some analysts predicted that it could generate as much as $25 billion in peak sales and become one of the best-selling drugs in the industry's history.
Bridgewater Associates slashed a stake in Apple, halved its Lilly investment, doubled down on Microsoft, and bought Moderna ...
Eli Lilly and Company (NYSE: LLY) today announced a $1 billion expansion of its Limerick, Ireland, manufacturing site to increase production of biologic active ingredients, including those for its ...
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 607.25% and ...
Forget Mounjaro: 1 Reason Investors Should Love Eli Lilly Stock Even More (Hint: I'm Not Talking About Zepbound) ...
Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today. The ...
Drugmaker Eli Lilly named Lucas Montarce as chief financial officer, filling a vacancy left by the departure of Anat ...
Eli Lilly said the Food and Drug Administration approved its treatment for moderate-to-severe eczema that isn't well controlled despite treatment with topical prescription therapies.
Eli Lilly and Company (NYSE:LLY) on Thursday announced a $1.8 billion investment to expand its manufacturing operations in Ireland. This decision will enhance the production of biologic active ...
Eli Lilly (LLY) stock gained as Citi resumed its covderage with a buy rating and $1,060 price target, citing optimism for its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback